De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sawai Group Holdings Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Sawai Group Holdings heeft een totaal eigen vermogen van ¥213.9B en een totale schuld van ¥88.5B, wat de schuld-eigenvermogensverhouding op 41.4% brengt. De totale activa en totale passiva bedragen respectievelijk ¥372.9B en ¥159.0B. De EBIT Sawai Group Holdings is ¥20.1B waardoor de rentedekking 44.2 is. Het heeft contanten en kortetermijnbeleggingen van ¥55.5B.

Belangrijke informatie

41.4%

Verhouding schuld/eigen vermogen

JP¥88.51b

Schuld

Rente dekkingsratio	44.2x
Contant	JP¥55.47b
Aandelen	JP¥213.89b
Totaal verplichtingen	JP¥159.00b
Totaal activa	JP¥372.89b

Recente financiële gezondheidsupdates

Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet

Jul 27

Is Sawai Group Holdings (TSE:4887) A Risky Investment?

Mar 06

Recent updates

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

Sep 04

Sawai Group Holdings Co., Ltd. (TSE:4887) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 12

Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet

Jul 27

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

May 28

Is There An Opportunity With Sawai Group Holdings Co., Ltd.'s (TSE:4887) 41% Undervaluation?

Apr 22

Is Sawai Group Holdings (TSE:4887) A Risky Investment?

Mar 06

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ¥218.9B ) 4887 } overtreffen de korte termijn passiva ( ¥72.0B ).

Langlopende schulden: De kortetermijnactiva 4887 ( ¥218.9B ) overtreffen de langetermijnschulden ( ¥87.0B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 15.4% ) 4887 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 4887 is de afgelopen 5 jaar gestegen van 36% naar 41.4%.

Schuldendekking: De schuld van 4887 wordt goed gedekt door de operationele kasstroom ( 21.1% ).

Rentedekking: De rentebetalingen op de schuld van 4887 worden goed gedekt door EBIT ( 44.2 x dekking).

Sawai Group Holdings Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet

Is Sawai Group Holdings (TSE:4887) A Risky Investment?

Recent updates

Upcoming dividend of JP¥78.00 per share

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

Sawai Group Holdings Co., Ltd. to Report Q2, 2025 Results on Nov 11, 2024

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Sawai Group Holdings Co., Ltd. (TSE:4887) Shares Could Be 47% Below Their Intrinsic Value Estimate

Sawai Group Holdings (TSE:4887) Has A Pretty Healthy Balance Sheet

Final dividend of JP¥78.00 announced

Sawai Group Holdings Co., Ltd. (TSE:4887) announces an Equity Buyback for 6,900,000 shares, representing 15.75% for ¥33,000 million.

Sawai Group Holdings Co., Ltd. to Report Q1, 2025 Results on Aug 09, 2024

Is Now The Time To Put Sawai Group Holdings (TSE:4887) On Your Watchlist?

Consensus EPS estimates increase by 24%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 25, 2024

Is There An Opportunity With Sawai Group Holdings Co., Ltd.'s (TSE:4887) 41% Undervaluation?

Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).

Bora Pharmaceuticals Co., LTD. (TWSE:6472) completed the acquisition of Sawai America Holdings Inc. from Sawai Group Holdings Co., Ltd. (TSE:4887).

Now 21% undervalued

Upcoming dividend of JP¥65.00 per share

Is Sawai Group Holdings (TSE:4887) A Risky Investment?

Consensus EPS estimates increase by 11%, revenue downgraded

Sawai Group Holdings Co., Ltd. to Report Q4, 2024 Results on May 13, 2024

Consensus EPS estimates increase by 40%, revenue downgraded

Now 21% undervalued

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 12% to JP¥5,863

Price target increased by 7.3% to JP¥5,586

Consensus EPS estimates fall by 12%

Sawai Group Holdings Co., Ltd. to Report Q3, 2024 Results on Feb 14, 2024

Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Upcoming dividend of JP¥65.00 per share at 2.8% yield

Price target increased by 9.9% to JP¥4,734

Sawai Group Holdings Co., Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Price target increased by 7.5% to JP¥4,308

First quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 10%

Consensus EPS estimates increase by 14%

Sawai Group Holdings Co., Ltd. to Report Q1, 2024 Results on Aug 09, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sawai Group Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half Year Ending September 2023 and Fiscal Year Ending March 31, 2024

Sawai Group Holdings Co., Ltd., Annual General Meeting, Jun 27, 2023

Price target decreased by 9.2% to JP¥4,169

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Sawai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Sawai Group Holdings Co., Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Sawai Group Holdings Co., Ltd. Announces Dividend for the Second Quarter Ending September 30, 2022, Payable on December 2, 2022; Provides Dividend Guidance for the Year Ending March 31, 2023

Upcoming dividend of JP¥65.00 per share

Sawai Group Holdings Co., Ltd. to Report Q2, 2023 Results on Nov 08, 2022

Price target increased to JP¥4,630

Sawai Group Holdings Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2023

Price target decreased to JP¥4,561

Sawai Group Holdings Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd. Announce Notice of Filing an Appeal in Patent Infringement Lawsuit Concerning Edirol Capsule

Sawai Group Holdings Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022

Sawai Group Holdings Co., Ltd. Provides Earnings Guidance for Period Ending September 2022 and Year Ending March 2023

Consensus EPS estimates fall by 83%

Less than half of directors are independent

Upcoming dividend of JP¥65.00 per share

Sawai Group Holdings Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022

Sawai Pharmaceutical Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2022

Second quarter 2022 earnings released: EPS JP¥71.13 (vs JP¥122 in 2Q 2021)

Upcoming dividend of JP¥65.00 per share

Full year 2021 earnings released: EPS JP¥282 (vs JP¥440 in FY 2020)

Full year 2021 earnings released: EPS JP¥282 (vs JP¥440 in FY 2020)

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven